Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 2/2006

01-04-2006 | Original paper

Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435

Authors: Lalita A. Shevde, Rajeev S. Samant, Jason C. Paik, Brandon J. Metge, Ann F. Chambers, Graham Casey, Andra R. Frost, Danny R. Welch

Published in: Clinical & Experimental Metastasis | Issue 2/2006

Login to get access
Metadata
Title
Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435
Authors
Lalita A. Shevde
Rajeev S. Samant
Jason C. Paik
Brandon J. Metge
Ann F. Chambers
Graham Casey
Andra R. Frost
Danny R. Welch
Publication date
01-04-2006
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 2/2006
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-006-9013-2

Other articles of this Issue 2/2006

Clinical & Experimental Metastasis 2/2006 Go to the issue

Original Paper

The p75NTR metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells

Original Paper

A surgically induced hypoxic environment causes changes in the metastatic behaviour of tumours in vitro

ORIGINAL PAPER

Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines

Review

Invadopodia: Specialized Cell Structures for Cancer Invasion

Original Paper

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits